JP2024514090A5 - - Google Patents
Info
- Publication number
- JP2024514090A5 JP2024514090A5 JP2023560010A JP2023560010A JP2024514090A5 JP 2024514090 A5 JP2024514090 A5 JP 2024514090A5 JP 2023560010 A JP2023560010 A JP 2023560010A JP 2023560010 A JP2023560010 A JP 2023560010A JP 2024514090 A5 JP2024514090 A5 JP 2024514090A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- cyclopropanecarboxamide
- triazole
- carboxamide
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163167504P | 2021-03-29 | 2021-03-29 | |
| US63/167,504 | 2021-03-29 | ||
| PCT/US2022/021815 WO2022212181A1 (en) | 2021-03-29 | 2022-03-24 | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514090A JP2024514090A (ja) | 2024-03-28 |
| JP2024514090A5 true JP2024514090A5 (https=) | 2025-04-01 |
Family
ID=81308277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560010A Pending JP2024514090A (ja) | 2021-03-29 | 2022-03-24 | ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶形態 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240190845A1 (https=) |
| EP (1) | EP4313974A1 (https=) |
| JP (1) | JP2024514090A (https=) |
| KR (1) | KR20230163469A (https=) |
| CN (1) | CN117377667A (https=) |
| WO (1) | WO2022212181A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7113023B2 (ja) * | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
| EP4387968B1 (en) * | 2021-08-20 | 2025-11-12 | Bristol-Myers Squibb Company | Crystal forms of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide |
| EP4713315A1 (en) * | 2023-05-15 | 2026-03-25 | Alivus Life Sciences Limited | Process for the preparation of deucravacitinib, and crystalline forms thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| JP7113023B2 (ja) * | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
| AU2018312349A1 (en) * | 2017-08-01 | 2020-02-06 | Theravance Biopharma R&D Ip, Llc | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors |
| KR102848769B1 (ko) * | 2018-05-31 | 2025-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태 |
| US11357775B2 (en) * | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| US12570637B2 (en) * | 2019-06-12 | 2026-03-10 | Bristol-Myers Squibb Company | Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide |
| CN114787152A (zh) * | 2019-12-27 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种bms-986165晶型及其制备方法和用途 |
-
2022
- 2022-03-24 CN CN202280036814.3A patent/CN117377667A/zh active Pending
- 2022-03-24 EP EP22716694.9A patent/EP4313974A1/en active Pending
- 2022-03-24 US US18/284,531 patent/US20240190845A1/en active Pending
- 2022-03-24 WO PCT/US2022/021815 patent/WO2022212181A1/en not_active Ceased
- 2022-03-24 KR KR1020237036640A patent/KR20230163469A/ko active Pending
- 2022-03-24 JP JP2023560010A patent/JP2024514090A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514090A5 (https=) | ||
| JP2024505063A5 (https=) | ||
| JP2020512380A5 (https=) | ||
| TWI406661B (zh) | ４-甲基-ｎ-〔３-（４-甲基-咪唑-１-基）-５-三氟甲基-苯基〕-３-（４-吡啶-３-基-嘧啶-２基胺基）-苯甲醯胺之結晶型 | |
| JP2023036708A5 (https=) | ||
| PL208708B1 (pl) | Polimorficzne formy chlorowodorku 1-4-(5-cyjanoindolo-3 -ylo) butylo-4- (2-karbamoilobenzofurano-5-ylo) piperazyny, sposób ich otrzymywania, ich zastosowanie w terapii zaburzeń medycznych i zawierające je kompozycje farmaceutyczne | |
| JP3665053B2 (ja) | 純結晶形態の５−クロロ−３−（４−メタンスルホニルフェニル）−６’−メチル−［２，３’］ビピリジニルおよび合成方法 | |
| JP2021523918A5 (https=) | ||
| AU2004291282A1 (en) | Pyridazin-3 (2H) -one derivatives and their use as PDE4 inhibitors | |
| JP2025511847A5 (https=) | ||
| JP2009521414A5 (https=) | ||
| JP2022533340A5 (https=) | ||
| AU2001264804A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JP2022551316A5 (https=) | ||
| JP2024540922A5 (https=) | ||
| JP2024529763A5 (https=) | ||
| JP2024521412A5 (https=) | ||
| JP2025102940A5 (https=) | ||
| TW202444341A (zh) | 萘胺類粒線體自噬誘導劑的固體形式、其製備方法、藥物組合物和用途 | |
| JP2022544272A5 (https=) | ||
| JP2022540922A5 (https=) | ||
| CA2447878C (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JP2022540678A5 (https=) | ||
| KR20120123270A (ko) | 메틸 ｛４，６－디아미노－２－〔１－（２-플루오로벤질）－１ｈ－피라졸로〔３，４－ｂ〕피리딘－３－일〕피리미딘－５－일｝카르바메이트의 신규한 용매화물 | |
| JP2024515770A5 (https=) |